factor
epidem
last
month
individu
quarantin
two
week
estim
econom
cost
billion
adenoviru
infect
may
caus
ard
fatal
outcom
infant
neonat
intens
care
unit
octob
april
patient
infant
children
mean
age
year
rang
year
intens
care
unit
present
fever
respiratori
symptom
andor
physician
diagnos
influenzalik
ill
test
adenoviru
infect
found
patient
test
adenovirusposit
mean
age
year
rang
year
adenoviru
infect
occur
neonat
age
day
one
four
neonat
develop
dissemin
adenovir
diseas
ard
fatal
outcom
whole
genom
sequenc
reveal
infant
infect
novel
human
adenoviru
type
although
pathogenesi
novel
viru
host
factor
contribut
diseas
sever
defin
yet
therefor
time
detect
human
adenoviru
infect
develop
effect
antivir
treatment
option
highli
vulner
age
group
urgent
need
mariko
saitoobata
tohoku
univers
graduat
school
medicin
miyagi
japan
human
enteroviru
member
picornavirida
famili
first
isol
pediatr
patient
hospit
lower
respiratori
infect
california
schiebl
et
al
rare
report
viru
link
respiratori
diseas
howev
spread
worldwid
centuri
oberst
et
al
tokarz
et
al
recent
report
number
case
acut
respiratori
infect
ari
significantli
increas
bigg
et
al
explor
possibl
reason
recent
increas
epidemiolog
clinic
characterist
children
analyz
hospitalbas
studi
children
clinic
diagnosi
sever
pneumonia
base
integr
manag
childhood
ill
imci
criteria
perform
sever
site
philippin
prospect
cohort
studi
children
symptom
ari
carri
biliran
island
nasopharyng
swab
np
taken
children
respiratori
virus
sampl
includ
influenza
viru
rhinoviru
respiratori
syncyti
viru
adenoviru
detect
rtpcr
confirm
detect
viru
determin
genogroup
dna
sequenc
conduct
among
total
np
sampl
collect
hospit
case
sampl
confirm
posit
among
np
sampl
collect
cohort
studi
posit
case
fatal
rate
hospit
posit
case
wherea
hospit
neg
case
p
phylogenet
analysi
show
philippin
strain
belong
lineag
hospit
posit
case
undetermin
respectivelti
signific
differ
case
fatal
rate
p
proport
sever
pneumonia
vs
p
similarli
posit
cohort
case
undetermin
respectivelti
interestingli
proport
case
diagnos
pneumoniasever
pneumoniaveri
sever
pneumonia
significantli
higher
p
result
studi
suggest
though
posit
rate
low
hospit
children
pneumonia
cohort
children
case
ari
philippin
associ
sever
pneumonia
philippin
strain
belong
domin
genogroup
associ
sever
diseas
cohort
children
confirm
import
pathogen
ari
possess
differ
epidemiolog
clinic
characterist
emi
takashita
nation
institut
infecti
diseas
tokyo
japan
continu
evolut
influenza
ha
na
glycoprotein
result
reduc
efficaci
antivir
drug
vaccin
exampl
singl
substitut
na
viru
confer
resist
nai
oseltamivir
peramivir
first
widespread
commun
cluster
mutant
viru
identifi
newcastl
australia
hurt
et
al
influenza
season
japan
larg
commun
cluster
influenza
viru
exhibit
crossresist
nai
oseltamivir
peramivir
takashita
et
al
takashita
et
al
influenza
season
surveil
nairesist
virus
throughout
japan
conduct
fluoresc
na
inhibit
assay
use
determin
suscept
virus
oseltamivir
peramivir
nai
zanamivir
laninamivir
accord
criteria
base
fold
chang
ic
valu
compar
median
ic
valu
subtypelineag
screen
virus
virus
found
possess
substitut
na
protein
two
mutant
virus
addit
substitut
na
protein
compar
singl
mutant
virus
dual
mutant
virus
exhibit
enhanc
crossresist
oseltamivir
peramivir
reduc
suscept
zanamivir
laninamivir
dual
mutant
viru
exhibit
reduc
vitro
replic
capac
dual
mutant
viru
retain
abil
grow
result
suggest
dual
substitut
exhibit
synergist
effect
compar
singl
chang
dual
mutant
viru
retain
viral
fit
potenti
spread
among
human
rueshandra
roosenhoff
erasmu
medic
center
rotterdam
netherland
assist
earli
detect
iav
resist
antivir
monitor
clinic
virolog
outcom
adult
children
infect
iav
accord
subtyp
suscept
influenza
resist
inform
studi
iri
conduct
unit
state
australia
franc
germani
hong
kong
norway
netherland
roch
period
oseltamivirtr
iavinfect
patient
followup
analyz
treatmentassoci
emergentc
resist
quantit
iav
rtpcr
perform
nasal
throat
swab
taken
day
baselin
day
respect
genotyp
phenotyp
viru
mutat
specif
rtpcr
next
gener
sequenc
origin
swab
perform
sanger
sequenc
na
inhibit
analysi
conduct
nastar
assay
cultur
materi
resist
mutat
detect
oseltamivirtr
patient
includ
infect
substitut
infect
strain
substitut
resist
mutat
first
detect
day
oseltamivirtr
patient
respect
next
visit
resist
mutant
clear
patient
resist
virus
isol
patient
less
viru
popul
detect
mutationspecif
rtpcr
detect
nastar
assay
howev
patient
resist
mutant
strain
major
speci
oseltamivir
resist
phenotyp
confirm
nastar
assay
strain
median
viral
rna
clearanc
day
resist
wildtyp
case
respect
p
signfic
differ
clearanc
strain
summari
oseltamivirresist
mutant
iav
detect
oseltamivirtr
patient
although
mutat
associ
major
substitut
ha
na
protein
potenti
aid
viral
fit
associ
delay
clearanc
viru
anoth
iri
substudi
viral
shed
suscept
oseltamivir
hospit
immunocompromis
patient
infect
iav
monitor
day
patient
clear
viru
four
patient
shed
resist
viru
fraaij
et
al
correl
symptom
sever
level
compromis
could
determin
updat
consolid
standard
guidelin
clinic
manag
sever
influenza
infect
paula
lister
great
ormond
street
hospit
london
uk
influenza
virus
particularli
zoonot
virus
avian
influenza
virus
subtyp
swine
influenza
virus
subtyp
pose
enorm
threat
global
public
health
march
first
case
human
infect
avianorigin
influenza
viru
report
china
far
five
influenza
epidem
wave
china
fifth
wave
begin
octob
reveal
steepest
increas
number
human
case
addit
emerg
highli
pathogen
strain
su
et
al
report
decemb
issu
updat
guidelin
prevent
infect
healthcar
set
chor
et
al
current
guidelin
clinic
manag
influenza
virus
publish
contribut
chines
nation
guidanc
influenza
standard
guidelin
clinic
manag
sever
influenza
updat
consolid
includ
new
evid
publish
recent
year
updat
consolid
standard
guidelin
develop
guidelin
steer
committe
gsc
guidelin
develop
group
gdg
global
repres
group
broad
expertis
includ
infecti
diseas
virolog
paediatr
public
health
import
area
new
evid
consider
includ
diagnost
includ
point
care
treatment
nai
includ
newer
licenc
nai
support
care
sever
critic
ill
patient
hypoxia
andor
shock
systemat
review
commiss
inform
guidelin
gdg
formul
recommend
base
evid
qualiti
assess
use
grade
approach
gsc
ensur
guidelin
must
meet
breadth
public
health
agenda
includ
subpopul
vulner
sever
diseas
updat
consolid
standard
guidelin
clinic
manag
sever
influenza
infect
expect
publish
earli
yinzhong
shen
shanghai
fudan
univers
china
influenza
viru
detect
isol
bird
secret
lpm
environ
closur
lpm
effect
reduc
human
risk
infect
yu
et
al
human
case
infect
sporad
sever
famili
cluster
limit
nonsustain
humantohuman
viru
transmiss
rule
limit
human
human
transmiss
hospit
set
togeth
risk
factor
overcrowd
ward
environ
perform
aerosolgener
procedur
report
fang
et
al
care
patient
ari
infect
prevent
control
ipc
guidelin
ari
patient
care
applic
patient
includ
earli
recognit
isol
patient
applic
routin
ipc
precaut
standard
precaut
patient
addit
precaut
select
patient
eg
airborn
precaut
high
risk
aerosolgener
procedur
ipc
strategi
healthcar
facil
earli
recognit
sourc
control
administr
control
environment
engin
control
person
protect
equip
lei
zhou
china
cdc
beij
china
june
case
human
infect
influenza
viru
report
fatal
earlier
start
steep
increas
number
human
case
viru
infect
observ
fifth
epidem
china
zhou
et
al
human
case
occur
eastern
southern
china
earlier
epidem
howev
six
provinc
central
western
china
without
previou
case
report
human
infect
fifth
epidem
indic
geograph
expans
case
comparison
earlier
epidem
epidemiolog
characterist
sex
age
patient
infect
viru
remain
unchang
proport
rural
resid
among
confirm
case
increas
fifth
wave
sever
remain
high
fifth
epidem
case
diagnos
sever
case
admit
intens
care
unit
case
report
exposur
poultri
includ
visit
lpm
ill
onset
contact
poultri
purchas
lpm
sinc
cluster
compris
case
least
epidemiologicallylink
confirm
case
identifi
includ
cluster
report
fifth
epidem
chang
size
number
cluster
per
epidem
evid
sustain
humantohuman
transmiss
human
case
confirm
sinc
caus
low
pathogen
avian
influenza
lpai
viru
infect
case
hpai
viru
infect
identifi
three
provinc
southern
china
fifth
epidem
preliminari
analysi
indic
hpai
virusinfect
patient
like
live
rural
area
exposur
sick
dead
poultri
admit
hospit
earlier
lpai
case
extens
effort
need
prevent
control
spread
lpai
hpai
virus
among
poultri
includ
rural
area
zhou
et
al
yuelong
shu
china
cdc
beij
china
yangtz
river
delta
region
locat
eastern
china
wellrecogn
origin
sourc
influenza
outbreak
base
evolutionari
analysi
virus
first
epidem
wave
pearl
river
delta
region
identifi
anoth
outbreak
sourc
virus
repeatedli
introduc
two
sourc
area
persist
circul
virus
occur
poultri
caus
continu
epidem
wave
intern
gene
continu
reassort
virus
ha
na
protein
evolv
genotyp
identifi
transient
genotyp
predomin
first
epidem
wave
replac
genotyp
second
third
epidem
wave
late
begin
three
patient
sever
clinic
symptom
confirm
infect
hpai
virus
virus
belong
yangtz
river
delta
lineag
four
amino
acid
insert
lysargthrala
ha
cleavag
site
enabl
hpai
viru
display
trypsinindepend
infect
addit
hpai
virus
acquir
substitut
ha
although
maintain
dual
receptorbind
prefer
hpai
ha
antigen
distinct
lpai
virus
virus
substitut
protein
confer
amantadin
resist
among
lpai
virus
test
nai
suscept
decreas
sensit
one
two
substitut
latter
confer
multidrug
resist
phenotyp
among
hpai
virus
test
also
reduc
sensit
three
substitut
isol
aros
posttreat
therefor
surveil
viru
especi
antivir
surveil
essenti
compon
pandem
prepared
xiaonan
zhang
behalf
junwen
hu
shanghai
fudan
univers
china
emerg
nairesist
variant
virus
na
substitut
pose
therapeut
challeng
studi
patient
infect
complic
pneumonia
nai
treatment
associ
reduct
viral
load
throat
swab
specimen
surviv
patient
howev
patient
persist
high
viral
load
throat
despit
antivir
therapi
becam
depend
extracorpor
membran
oxygen
na
substitut
identifi
two
patient
also
receiv
system
corticosteroid
treatment
one
wildtyp
sequenc
note
day
commenc
nai
treatment
resist
mutant
domin
day
commenc
treatment
use
limit
serial
passag
presenc
oseltamivir
plaqu
purif
variant
lineag
isol
patient
clinic
evid
resist
oseltamivir
vitro
cellbas
assay
confirm
high
level
resist
viru
carri
substitut
oseltamivir
carboxyl
moder
level
resist
zanamivir
peramivir
nonnai
antivir
ribavirin
effici
inhibit
variant
wildtyp
virus
cellbas
assay
combin
nai
nonnai
exhibit
mark
synergist
effect
variant
cell
cultur
howev
combin
two
nonnai
ribavirin
exhibit
synerg
mutant
viru
experiment
infect
mice
variant
show
delay
onset
symptom
reduc
viral
load
attenu
lethal
compar
wildtyp
studi
suggest
nonnai
test
clinic
patient
sustain
high
viral
load
possibl
drug
combin
regimen
plu
ribavirin
test
anim
model
realtim
rtpcr
singl
nucleotid
polymorph
probe
develop
differenti
mutant
strain
mix
viru
popul
human
specimen
screen
patient
undergo
oseltamivir
therapi
identifi
virus
mix
rk
sequenc
previous
detect
yiwei
tang
memori
sloan
ketter
cancer
center
new
york
usa
clinic
manifest
respiratori
viru
infect
usual
nonspecif
signific
overlap
viral
bacteri
noninfecti
caus
new
technolog
improv
multiplex
capabl
allow
detect
differenti
multipl
virus
singl
respiratori
sampl
order
clinic
use
clinician
want
rapid
turn
around
multipl
pathogen
detect
clinic
microbiolog
laboratori
handl
low
medium
specimen
volum
platform
prefer
allow
simpl
workflow
use
minim
train
afford
rapid
turnaround
time
howev
platform
capabl
larg
volum
test
batch
test
high
throughput
platform
use
unexpect
increas
test
volum
nosocomi
outbreak
peak
influenza
season
pandem
one
system
work
situat
laboratorian
clinician
know
limit
test
platform
avail
yeme
wang
xuan
wu
hospit
capit
medic
univers
beij
china
influenza
viru
mortal
rate
clinic
sever
assess
tool
need
help
triag
patient
infect
current
sever
assess
tool
test
popul
goal
studi
develop
new
clinic
sever
tool
compar
current
avail
tool
psi
pneumonia
sever
index
fine
et
al
smartcop
charl
et
al
systol
blood
pressur
multilobar
chest
radiographi
involv
albumin
level
respiratori
rate
tachycardia
confus
oxygen
arteri
ph
lim
et
al
confus
urea
nitrogen
respiratori
rate
blood
pressur
year
age
older
data
collect
patient
hospit
influenza
infect
china
deriv
cohort
construct
clinic
data
patient
hospit
april
march
patient
complet
data
mortal
deriv
cohort
multivari
logist
regress
perform
identifi
clinic
featur
admiss
hospit
associ
mortal
within
day
result
convert
simpl
pointbas
sever
tool
base
creatinin
level
lymphocyt
count
age
mortal
valid
cohort
risk
factor
associ
mortal
creatinin
point
lymphocyt
count
point
age
point
year
point
point
mmhg
point
score
system
call
clap
deriv
score
system
valid
cohort
compil
clinic
data
patient
hospit
octob
march
sensit
specif
clap
admiss
identifi
mortal
respect
highest
auroc
clap
score
ci
psi
score
ci
compar
ci
smartcop
p
compar
clap
ci
p
compar
clap
clap
simpl
score
tool
util
predict
outcom
patient
infect
influenza
viral
pneumonia
investig
antibodi
dynam
random
studi
japanes
pediatr
patient
influenza
viru
infect
treatment
four
neuraminidas
inhibitor
nobuo
hirotsu
hirostu
clinic
kawasaki
japan
known
antivir
treatment
may
affect
develop
adapt
immun
respons
influenza
infect
studi
previous
report
option
ix
control
influenza
particip
year
age
present
within
hour
ill
onset
randomli
alloc
administ
one
four
nai
oral
oseltamivir
inhal
zanamivir
intraven
peramivir
inhal
laninamivir
primari
endpoint
time
undetect
viru
titer
peramivir
show
shorter
time
viral
clearanc
compar
oseltamivir
adjust
p
analysi
examin
adapt
immun
respons
measur
hemagglutinininhibit
assay
hai
differ
among
treatment
group
approxim
enrol
patient
infect
influenza
viru
influenza
antibodi
level
evalu
three
timepoint
baselin
day
day
signific
differ
hai
titer
increas
ratio
baselin
day
visit
treatment
prior
vaccin
prior
influenza
infect
prior
famili
histori
influenza
ill
associ
higher
pretreat
antibodi
level
higher
antibodi
increas
day
day
correl
faster
resolut
viral
shed
nelson
lee
chines
univers
hong
kong
hong
kong
sar
china
hypercytokinemia
seen
sever
influenza
associ
poor
outcom
macrolid
antiinflammatori
properti
may
attenu
cytokin
level
acut
influenza
kanoh
rubin
random
openlabel
multicent
trial
among
adult
hospit
laboratoryconfirm
influenza
adult
year
age
lower
respiratori
tract
infect
present
within
day
onset
ill
elig
studi
subject
elig
take
corticosteroid
baselin
qtc
prolong
ekg
particip
random
ratio
receiv
oseltamivir
azithromycin
mgday
versu
oseltamivir
alon
day
primari
outcom
chang
plasma
cytokinechemokin
concentr
time
day
fifti
patient
random
studi
treatment
arm
compar
baselin
characterist
age
year
influenza
viral
load
similar
macrolid
treatment
associ
lower
proinflammatori
cytokin
reduct
baselin
vs
p
vs
p
vs
p
vs
p
howev
durat
fever
durat
symptom
viral
shed
differ
two
treatment
arm
influenza
viru
acid
polymeras
pa
promis
antivir
target
essenti
role
viru
transcript
new
pa
protein
endonucleas
inhibitor
jone
et
al
test
influenza
b
virus
mdck
differenti
human
bronchial
epitheli
cell
inhibit
replic
multipl
strain
influenza
b
virus
well
nairesist
variant
mean
ec
nm
lethal
balbc
mous
model
establish
use
tissu
cultur
infecti
dose
tcid
tcid
viru
mice
treat
mgkgday
twice
daili
day
start
hour
hour
viru
inocul
dose
level
exhibit
reduc
morbid
increas
surviv
reduc
lung
viru
load
decreas
lung
patholog
compar
untreat
control
resist
observ
virus
isol
drugtreat
mous
lung
viru
reduc
sensit
select
passag
mdck
increas
concentr
substitut
pa
endonucleas
domain
howev
circul
virus
chang
topaz
trial
phase
iib
studi
pimodivir
formerli
monotherapi
combin
oseltamivir
treatment
acut
uncompl
season
influenza
lorant
leopold
janssen
titusvil
new
jersey
usa
pimodivir
subunit
inhibitor
influenza
polymeras
fu
et
al
phase
ii
studi
evalu
safeti
potenti
efficaci
pimodivir
adult
year
age
acut
uncompl
influenza
viru
infect
present
less
hour
symptom
elig
studi
particip
random
receiv
placebo
pimodivir
mg
pimodivir
mg
combin
pimodivir
mgoseltamivir
mg
day
particip
screen
random
use
primari
analysi
demograph
balanc
across
treatment
arm
caucasian
femal
median
age
year
compar
placebo
mg
pimodivir
result
greater
decreas
qrtpcr
area
curv
auc
viral
load
day
compar
mg
vs
log
copiesml
combin
pimodivir
oseltamivir
demonstr
reduct
compar
pimodivir
mg
log
copiesml
p
chang
median
time
resolut
symptom
pimodivir
mg
hour
pimodivir
mg
hour
pimodivir
oseltamivir
hour
placebo
alon
hour
common
advers
event
diarrhea
typic
mild
similar
across
treatment
arm
although
pimodivir
show
statist
signific
decreas
viral
area
curv
differ
associ
improv
clinic
benefit
dosag
mg
pimodivir
select
phase
iii
studi
random
studi
combin
antivir
treatment
influenza
john
beigel
leido
biomed
research
support
niaid
bethesda
md
usa
preclin
data
suggest
combin
antiinfluenza
antivir
could
effect
oseltamivir
alon
treatment
influenza
random
blind
multicent
phase
ii
trial
unit
state
thailand
mexico
argentina
australia
particip
either
year
age
older
chronic
medic
condit
andor
obes
confirm
influenza
b
elig
studi
enrol
subject
randomli
assign
receiv
either
combin
oseltamivir
amantadin
ribavirin
oseltamivir
alon
day
follow
day
primari
endpoint
percentag
particip
viru
detect
pcr
nasopharyng
swab
day
particip
enrol
random
seven
particip
exclud
itt
popul
random
appropri
withdrew
take
studi
medic
primari
analysi
includ
particip
exclud
pilot
phase
without
influenza
confirm
central
laboratori
without
endpoint
sampl
particip
combin
arm
viru
detect
day
compar
ci
p
control
arm
benefit
clinic
outcom
across
multipl
paramet
durat
clinic
symptom
day
combin
arm
vs
day
oseltamivir
monotherapi
p
durat
fever
vs
day
p
time
feel
good
influenza
ill
vs
day
p
time
return
preill
physic
function
use
physic
domain
vs
day
p
common
advers
event
nausea
vs
vomit
vs
diarrhea
vs
occur
similar
proport
arm
although
oseltamivir
amantadin
ribavirin
show
statist
signific
decreas
viral
shed
day
rel
oseltamivir
monotherapi
differ
associ
clinic
benefit
hongji
yu
school
public
health
fudan
univers
china
china
geograph
econom
climatolog
divers
countri
popul
approxim
billion
factor
part
contribut
toward
substanti
influenza
mortal
burden
estim
excess
death
per
southern
northern
citi
interpandem
season
feng
et
al
although
season
influenza
vaccin
introduc
china
includ
nation
immun
program
influenza
vaccin
coverag
still
rel
low
mainli
elderli
wealthier
citi
addit
substanti
vaccin
rate
divers
observ
among
lowand
highincom
citi
provinc
basi
multiyear
laboratoryconfirm
influenza
surveil
data
repres
larg
major
chines
popul
three
epidemiolog
region
identifi
influenza
viru
infect
northern
provinc
latitud
experi
winter
epidem
southern
provinc
latitud
experi
peak
activ
spring
provinc
intermedi
latitud
experi
semiannu
epidem
cycl
therefor
optim
northern
china
follow
time
vaccin
typic
recommend
northern
hemispher
annual
campaign
start
octob
contrast
southern
chines
provinc
accommod
influenza
activ
peak
apriljun
henc
vaccin
would
best
initi
februarymarch
year
broadli
coincid
recommend
time
vaccin
southern
hemispher
nation
influenza
surveil
network
launch
china
influenza
pandem
southern
chines
provinc
three
northern
provinc
includ
gansu
liaon
tianjin
conduct
fullyear
influenza
surveil
although
northern
provinc
conduct
halfyear
surveil
network
includ
provincialand
prefecturelevel
center
diseas
control
prevent
cdc
sentinel
hospit
situat
provinc
current
provinc
yearround
influenza
surveil
sentinel
hospit
report
number
total
outpati
visit
number
visit
outpati
ili
age
group
retrospect
telephon
survey
estim
cost
treatment
outpati
influenza
usd
inpati
nation
sentinel
hospitalbas
influenza
surveil
network
surveil
sari
central
china
show
outpati
hospit
mortal
econom
burden
associ
influenza
substanti
china
signific
variat
observ
influenzaassoci
ili
burden
sari
hospit
provinc
age
influenza
viru
type
one
survey
approxim
million
patient
present
sentinel
hospit
ili
test
influenza
posit
surveil
among
hospit
jingzhou
show
sari
case
test
confirm
influenza
includ
age
year
yu
et
al
mark
differ
season
influenza
b
virus
determin
china
experienc
annual
influenza
b
activ
winter
activ
surveil
hospit
patient
acut
lower
respiratori
infect
reveal
spectrum
viral
agent
provinc
china
influenza
patient
rsv
patient
piv
patient
adenoviru
patient
bocaviru
patient
human
metapneumoviru
patient
hcov
patient
bin
cao
jiem
qu
shanghai
ruijin
hospit
shanghai
china
assembl
infecti
diseas
chines
thorac
societi
revis
clinic
practic
guidelin
cap
publish
updat
chines
version
april
qu
cao
version
base
new
evid
emerg
recent
decad
etiolog
profil
cap
china
advanc
laboratori
diagnosi
newer
antiinfect
therapi
access
effect
vaccin
torr
et
al
main
content
guidelin
includ
definit
diagnosi
cap
assess
cap
sever
criteria
hospit
admiss
etiolog
diagnosi
antiinfect
therapi
adjunct
therapi
assess
initi
therapi
criteria
discharg
unusu
type
cap
prophylaxi
recommend
grade
base
strength
evid
accord
intern
standard
streptococcu
pneumonia
mycoplasma
pneumonia
commonest
bacteri
pathogen
distinct
resist
pattern
penicillin
macrolid
gramneg
pathogen
eg
klebsiella
pneumonia
e
coli
frequent
found
special
popul
elderli
respiratori
virus
constitut
case
influenza
import
pathogen
communityacquir
mrsa
infect
remain
rare
score
recommend
tool
assist
decis
hospit
chines
patient
use
culturebas
antigenbas
molecular
assay
well
biochem
marker
eg
procalcitonin
diagnosi
discuss
empir
antibacteri
antivir
recommend
base
meet
report
antivir
research
epidemiolog
data
clinic
scenario
resist
profil
nai
recommend
influenza
pneumonia
influenza
vaccin
pneumococc
vaccin
polysaccharid
conjug
recommend
prevent
english
version
practic
guidelin
prepar
lili
jiang
nation
univers
singapor
singapor
healthcar
worker
hcw
may
play
signific
role
transmit
pathogen
within
hospit
set
even
hospit
commun
vice
versa
prospect
contactdiari
survey
hospitalbas
hcw
public
hospit
singapor
investig
contact
pattern
compar
work
adult
gener
popul
particip
record
contact
pattern
convers
word
skintoskin
contact
period
demograph
contact
person
locat
contact
contact
durat
altogeth
hcw
work
adult
report
contact
respect
hcw
report
workrel
contact
median
vs
less
household
contact
vs
hcw
also
workrel
skintoskin
contact
vs
among
differ
hcw
subgroup
doctor
report
highest
wardbas
nurs
report
lowest
total
workrel
contact
vs
howev
skinto
skin
workrel
contact
highest
wardbas
nurs
compar
hcw
vs
multivari
linear
regress
show
signific
differ
workrel
contact
among
variou
hcw
subgroup
adjust
gender
institut
effect
conclud
hcw
experienc
physic
contact
gener
popul
may
place
higher
risk
acquir
spread
infect
keisuk
yoshihara
institut
tropic
medicin
nagasaki
univers
nagasaki
japan
human
metapneumoviru
hmpv
known
caus
ari
especi
common
among
children
edward
et
al
howev
detail
clinic
molecular
epidemiolog
inform
hmpv
remain
limit
develop
countri
season
pattern
molecular
character
hmpv
pediatr
patient
hospit
ari
central
vietnam
monitor
part
populationbas
ari
surveil
program
total
case
enrol
test
posit
hmpv
multiplex
pcr
assay
yearli
hmpv
incid
per
among
children
year
prior
increas
per
period
season
trend
present
featur
includ
wheez
pneumonia
respect
hmpv
groupa
b
cocircul
groupa
predomin
season
timesc
phylogenet
tree
f
gene
show
recent
domin
lineag
diverg
around
around
hpd
around
becam
domin
multivari
analysi
result
indic
case
infect
lineag
clinic
sever
adjust
ci
ci
wheez
pneumonia
respect
group
b
viru
infect
appear
milder
find
indic
import
hmpv
pediatr
ari
hospit
provid
use
inform
futur
surveil
vaccin
develop
johnsebastian
eden
univers
sydney
sydney
nsw
australia
rsv
one
import
caus
sever
respiratori
infect
infant
young
children
well
older
adult
immunocompromis
lee
et
al
shi
et
al
howev
understand
dynam
drive
ongo
evolut
epidemiolog
rsv
transmiss
human
rather
limit
studi
genet
divers
well
potenti
baselin
resist
novel
therapeut
genom
rsv
strain
collect
adult
pediatr
patient
australia
rsva
n
rsvb
n
amplifi
sequenc
use
kb
overlap
rtpcr
strategi
target
rsva
rsvb
subtyp
nextera
xt
librari
prepar
sequenc
use
illumina
miseq
follow
de
novo
assembl
rsv
sequenc
align
global
refer
analyz
use
phylodynam
approach
distinct
season
observ
infect
occur
late
winter
period
subtl
shift
season
rel
predomin
rsva
rsvb
strain
multipl
cocircul
lineag
identifi
australian
strain
dispers
throughout
global
divers
spatial
tempor
cluster
observ
local
region
scale
highlight
complex
finescal
dynam
eg
institut
outbreak
well
gene
flow
within
asiaoceania
region
gene
flow
local
endem
lineag
consist
respiratori
pathogen
suggest
viral
traffic
driven
human
movement
interact
strongtempor
structur
also
observ
similar
mean
rate
evolutionari
chang
global
scale
rsva
rsvb
subtyp
nucleotid
substitut
per
site
per
year
subssiteyear
subssiteyear
respect
like
previou
observ
variat
found
g
protein
intergen
region
howev
fix
chang
observ
within
fusion
protein
potenti
antigen
site
recent
rsva
strain
resist
associ
mutat
f
protein
polymeras
gene
seem
rare
data
add
understand
rsv
genet
divers
transmiss
diseas
dynam
may
benefit
futur
vaccin
design
norosoa
razanajatovo
institut
pasteur
de
madagascar
antananarivo
madagascar
etiolog
incid
sari
among
hospit
patient
part
ongo
surveil
program
madagascar
upper
respiratori
sampl
analyz
influenza
rsv
rhinoviru
use
realtim
rtpcr
assay
total
patient
sari
patient
enrol
median
age
year
case
n
children
year
old
detect
rate
influenza
rsv
rhinovirus
respect
age
group
year
affect
rsv
p
wherea
age
group
year
p
year
p
frequent
infect
influenza
virus
overal
incid
sari
per
personyear
vari
significantli
year
year
incid
influenzaassoci
sari
per
personyear
highest
incid
age
group
year
per
personyear
p
overal
incid
rsv
per
personyear
highest
incid
among
children
age
year
per
personyear
p
data
indic
diseas
burden
caus
respiratori
virus
high
african
countri
particularli
among
children
highlight
import
continu
surveil
provid
meet
report
antivir
research
data
plan
public
health
measur
region
lafond
et
al
mcmorrow
et
al
peter
openshaw
imperi
colleg
london
unit
kingdom
sever
influenza
may
part
result
overexuber
host
respons
driven
high
viral
load
bacteri
overgrowth
usual
resid
pathogen
speci
pneumonia
h
influenza
also
contribut
morbid
mortal
due
overlap
clinic
featur
empir
antibacteri
treatment
frequent
prescrib
perhap
unnecessarili
wherea
empir
antivir
treatment
may
underutil
myle
et
al
therefor
import
distinguish
mechan
refin
direct
specif
antivir
antibacteri
potenti
immunomodulatori
therapi
case
clear
therapi
use
host
respons
infect
might
act
indic
exampl
analysi
transcript
signatur
peripher
blood
suarez
et
al
depend
respons
sever
phase
complic
influenza
infect
remain
unclear
comprehens
analysi
whole
blood
rna
signatur
localsystem
mediat
carri
cohort
adult
influenzalik
ill
season
mechan
sever
acut
influenza
consortium
mosaic
cole
et
al
interferonrel
antivir
pathway
gene
overexpress
earli
phase
ill
day
follow
activ
inflammatori
cell
pathway
includ
neutrophil
monocyt
nk
cell
day
molecular
score
relat
sever
affect
bacteri
sepsi
depend
critic
time
sinc
onset
symptom
identif
specif
pattern
immun
activ
might
amen
therapeut
manipul
may
ultim
assist
manag
influenza
requir
care
interpret
hui
li
capit
medic
univers
beij
china
role
cell
respons
influenza
fulli
character
zhao
et
al
antigenspecif
cell
respons
correl
diseas
sever
examin
patient
influenza
infect
china
sampl
taken
acut
phase
day
recoveri
phase
day
test
live
viru
peptid
pool
influenza
virus
longitudin
chang
influenzaspecif
cell
respons
without
pneumonia
character
cell
activ
migrationrel
cytokineschemokin
plasma
measur
compar
milder
infect
influenzaspecif
cell
respons
viru
shed
elev
patient
pneumonia
acut
phase
ill
effector
cell
highlyexpress
inhibitori
immun
receptor
domin
respons
secret
recoveri
phase
effector
memori
cell
highlyexpress
higher
sever
infect
compar
mild
infect
magnitud
cell
respons
correl
pneumonia
sever
indic
lung
injuri
score
apach
ii
score
addit
cell
activ
migrationrel
cytokineschemokin
associ
diseas
sever
thu
cell
respons
may
play
role
pathogenesi
diseas
progress
pneumonia
jieru
wang
univers
pittsburgh
pittsburgh
usa
absentinmelanoma
inflammasom
import
host
respons
rang
bacteri
viral
infect
littl
known
role
iav
infect
activ
dsdna
upon
infect
cell
lead
cleavag
activ
cleavag
activ
form
role
studi
use
knockout
mice
infect
lethal
dose
iav
mice
induc
dsdna
releas
activ
releas
cleav
lung
significantli
reduc
addit
defici
mice
exhibit
attenu
lung
injuri
fewer
neutrophil
infiltr
improv
surviv
iav
challeng
viru
burden
lung
unalt
defici
shown
affect
adapt
immun
respons
iav
infect
vitro
experi
treat
defici
human
mous
lung
alveolar
macrophag
type
ii
cell
indic
macrophagespecif
function
regul
iavstimul
proinflammatori
respons
find
suggest
influenza
infect
activ
inflammasom
may
play
import
role
iavinduc
lung
injuri
mortal
identif
essenti
host
factor
uncoat
step
influenza
viru
entri
jihy
lee
institut
pasteur
korea
republ
korea
use
sirna
host
gene
human
lung
epitheli
cell
target
screen
effect
multicycl
infect
influenza
viru
sirna
decreas
iav
infect
topscor
sirna
valid
deadbox
rna
helicas
identifi
essenti
factor
iav
replic
deplet
sirna
result
log
decreas
viru
yield
singleand
multicycl
replic
kinet
growth
defect
also
found
influenza
subtyp
includ
type
b
effect
earli
sinc
hour
infect
pi
level
mrna
vrna
reduc
normal
rnp
import
nucleu
hour
pi
littl
np
stain
nucleu
furthermor
stain
cytoplasm
indic
known
function
mrna
nuclear
export
block
earlier
uncoat
step
contrast
other
show
enhanc
nuclear
export
influenza
mrna
diot
et
al
larisa
gubareva
center
diseas
control
prevent
atlanta
ga
usa
still
establish
correl
clinic
relev
resist
nai
virus
may
show
reduc
fit
vitro
vivo
other
retain
fit
influenza
wildtyp
wt
mutant
virus
propag
plaquepurifi
antivir
research
character
nai
assay
genom
sequenc
mice
viru
still
similar
mld
wherea
virus
show
higher
pathogen
lower
mld
mice
infect
mld
wt
oseltamivir
treatment
reduc
lung
viru
titer
contrast
oseltamivir
treat
mice
infect
viru
show
decreas
viru
titer
still
signific
weight
loss
sixteen
recombin
na
also
gener
use
transient
baculoviru
express
system
test
avail
nai
seen
subtyp
caus
reduc
inhibit
ri
highli
reduc
inhibit
hri
depend
nai
test
confer
hri
oseltamivir
convers
harbor
display
hri
oseltamivir
set
apart
exhibit
normal
inhibit
ferret
model
marjuki
et
al
viru
show
reduc
replic
log
tcid
reduct
viral
titer
virus
replic
similarli
wt
treatment
oseltamivir
mgkgdose
bid
day
show
log
reduct
nasal
wash
viral
titer
reduct
detect
infect
either
virus
small
reduct
viral
titer
seen
anim
ferret
infect
wt
viru
treat
oseltamivir
resist
virus
chang
emerg
virusinfect
ferret
day
treatment
laboratori
test
bd
iart
assay
design
detect
resist
virus
clinic
sampl
gubareva
et
al
pure
popul
resist
readili
detect
howev
mix
popul
na
lower
activ
need
popul
detect
howev
modifi
buffer
lower
ph
enabl
detect
mutant
one
viru
also
ha
mutat
viru
appear
reduc
sensit
vitro
vivo
genentech
human
mab
marjuki
et
al
highlight
challeng
develop
phenotyp
assay
resist
new
mab
develop
rvi
therapeut
understand
antivir
target
compound
identifi
use
system
biolog
approach
regul
pathogen
influenza
viru
yoshi
kawaoka
univers
wisconsin
madison
wisconsin
usa
univers
tokyo
tokyo
japan
system
biolog
approach
use
investig
critic
host
regul
potenti
antivir
target
use
microarray
analysi
virusinfect
cell
transcript
data
set
cell
compar
potenti
critic
gene
target
use
sirna
knockdown
look
knockdown
result
increas
viru
titer
led
chang
viru
titer
use
luciferas
report
system
compound
screen
hous
librari
ic
less
nm
cc
greater
nm
priorit
base
exist
human
approv
toxic
mice
inform
avail
deliveri
rout
mous
challeng
model
identifi
compound
protect
mice
increas
pathogen
aim
identifi
drug
affect
host
respons
network
identifi
mechan
affect
pathogen
peter
openshaw
imperi
colleg
london
unit
kingdom
rsv
infect
ciliat
cell
respiratori
mucosa
caus
respiratori
diseas
variabl
sever
hrsv
infect
twothird
children
first
year
life
virtual
children
age
repeatedli
reinfect
human
throughout
life
appar
induc
immunolog
amnesia
host
winter
one
six
pediatr
bed
occupi
bronchiol
patient
caus
rsv
rsv
also
associ
high
mortal
stem
cell
transplant
mortal
frail
elderli
rsv
also
import
exacerb
copd
asthma
standard
method
diagnosi
rsv
use
nasopharyng
aspir
npa
obtain
sampl
howev
unpleas
may
inaccur
nasosorpt
thwait
et
al
use
absorpt
matrix
allow
measur
rsv
load
mucos
inflammatori
respons
show
correl
diseas
sever
viru
load
length
hospit
stay
seen
npa
sampl
antivir
yet
approv
palivizumab
human
monoclon
antibodi
use
long
term
prophylaxi
high
risk
infant
perron
et
al
potent
small
molecul
inhibitor
target
rsv
f
protein
inhibit
f
proteinmedi
celltocel
fusion
doubleblind
placebo
control
trial
healthi
adult
challeng
rsv
devincenzo
et
al
test
variou
dose
primari
endpoint
auc
viral
load
secondari
endpoint
mucu
weight
symptom
score
treatment
reduc
viral
load
sever
clinic
diseas
oral
bioavail
prodrug
cytidin
nucleosid
analogu
devincenzo
et
al
phosphoryl
form
nucleosid
triphosph
analogu
inhibit
rsv
polymeras
l
limit
viru
replic
rsv
challeng
studi
variou
dose
rapid
rsv
clearanc
greater
reduct
viru
load
decreas
mucu
weight
compar
placebo
group
stephen
toovey
ark
bioscienc
shanghai
china
small
molecul
rsv
fusion
protein
inhibitor
passag
presenc
led
emerg
resist
virus
cc
greater
cell
immunocompromis
mous
model
mgkg
mgkg
result
log
decreas
viru
titer
respect
nontox
juvenil
adult
rat
monkey
oral
well
toler
healthi
adult
volunt
singl
sad
multipl
ascend
dose
mad
reynold
seriou
advers
event
report
safeti
concern
signal
emerg
maximum
dose
mg
sad
mg
daili
mad
initi
open
label
phase
studi
infant
hospit
natur
rsv
infect
convert
doubleblind
placebo
control
phase
iia
studi
ongo
pk
clinic
virolog
safeti
review
shown
better
bioavail
anticip
mean
lower
dose
may
feasibl
studi
ongo
still
blind
mani
patient
shown
improv
symptom
antivir
research
use
probiot
rvi
mitig
liisa
lehtoranta
dupont
nutrit
health
kantvik
finland
probiot
defin
live
microorgan
administr
adequ
amount
confer
health
benefit
host
commerci
probiot
belong
genera
lactobacillu
bifidobacterium
probiot
may
favor
effect
viral
ari
metaanalys
trial
suggest
probiot
may
reduc
incid
durat
viral
ari
antibiot
use
coldrel
school
absenc
taken
prophylact
hao
et
al
howev
qualiti
evid
low
random
doubl
blind
placebo
control
trial
pct
healthi
activ
men
women
australia
show
delay
respiratori
viru
infect
take
probiot
compar
placebo
west
et
al
anoth
random
pct
determin
effect
administr
bifidobacterium
animali
subspeci
lacti
innat
adapt
host
respons
experiment
rhinoviru
challeng
turner
et
al
supplement
taken
day
post
challeng
nasal
wash
sampl
taken
viru
load
chemokin
ligand
level
probiot
result
higher
level
nasal
prior
challeng
lower
level
postinfect
compar
placebo
probiot
use
associ
reduct
nasal
lavag
viru
titer
differ
symptom
score
infect
rate
bin
cao
china
japan
friendship
hospit
beij
china
tradit
chines
medicin
tcm
use
thousand
year
china
may
compos
extract
singl
multipl
plant
speci
materi
variou
formul
may
antivir
activ
inhibit
viru
replic
modul
immun
respons
follow
report
antivir
effect
preclin
studi
paeonia
delavayi
root
extract
significantli
inhibit
na
activ
two
seven
identifi
constitu
significantli
inhibit
na
li
et
al
cell
anim
test
done
b
lianhuaqingwen
capsul
inhibit
prolifer
variou
strain
influenza
virus
plaqu
reduct
assay
impair
nuclear
export
viral
rnp
ding
et
al
also
suppress
virusinduc
nfkb
activ
reduc
level
inflammatori
cytokin
c
laggera
pterodonta
benth
extract
fraction
one
compon
act
earli
stage
influenza
viru
replic
prevent
increas
express
cytokin
chemokin
puerana
lobata
ohwi
p
lobata
show
antivir
activ
hrsvinduc
plaqu
format
cell
act
earli
stage
infect
inhibit
viral
attach
intern
lin
et
al
scutellaria
baicalensi
root
extract
fraction
baicalin
found
respons
antivir
activ
rsv
plaqu
assay
mous
model
baicalin
treatment
result
reduct
lymphocyt
infiltr
gene
express
proinflammatori
factor
treatment
moder
reduc
rsv
titer
recov
lung
tissu
shi
et
al
e
andrographolid
essenti
activ
ingredi
extract
plant
andrographi
paniculata
howev
poor
water
solubl
limit
bioavail
oral
administr
andrographolid
deriv
reduc
death
rate
inhibit
lung
consolid
reduc
viral
titer
lung
infect
mice
chen
et
al
deriv
report
inhibit
replic
viru
cell
yuan
et
al
trial
design
test
andrographolid
patient
hospit
cap
primari
outcom
time
clinic
stabil
secondari
outcom
includ
durat
fever
hospit
stay
durat
antibiot
administr
mgday
inject
approxim
patient
need
howev
mani
unknown
design
trial
includ
dosag
pkpd
data
ae
etc
addit
main
compon
tcm
inject
andrographolid
total
ester
rather
singl
chemic
compound
henc
extract
purif
activ
ingredi
raw
herb
may
affect
safeti
effect
compar
extract
clinic
evalu
f
maxingshiganyinqiaosan
prospect
nonblind
random
control
trial
person
laboratoryconfirm
influenza
treat
oseltamivir
mg
twice
daili
maxingshiganyinqiaosan
decoct
compos
chines
herbal
medicin
ml
time
daili
oseltamivir
plu
maxingshiganyinqiaosan
intervent
wang
et
al
intervent
control
given
day
oseltamivir
maxingshiganyinqiaosan
alon
combin
reduc
time
fever
resolut
patient
influenza
viru
infect
greater
reduct
combin
therapi
howev
differ
symptom
score
compar
control
g
xuebij
inject
formula
compos
five
medicin
herb
multicent
blind
rpct
evalu
patient
sever
pneumonia
measur
efficaci
reduc
pneumonia
sever
risk
rate
wang
et
al
unpublish
result
suggest
improv
clinic
symptom
day
decreas
mortal
inhibitor
viral
host
direct
must
effect
strain
influenza
includ
highli
pathogen
strain
low
likelihood
resist
novel
mechan
long
treatment
window
improv
patient
outcom
includ
prevent
life
threaten
complic
high
risk
patient
candid
drug
initi
test
vitro
follow
efficaci
test
mous
model
influenza
infect
test
warrant
gapfil
preclin
servic
avail
advanc
product
toward
regulatori
approv
clinic
test
unit
meet
report
antivir
research
phase
studi
offer
promis
therapeut
candid
similar
servic
avail
evalu
new
compound
panel
respiratori
virus
array
compound
test
influenza
includ
blocker
amantadin
resist
mutant
bispecif
reagent
target
cell
epitop
tri
improv
nai
wider
applic
anti
ha
stem
antibodi
peptid
flufurtid
arbidol
small
molecul
pa
endonucleas
inhibitor
polymeras
inhibitor
cap
snatch
inhibitor
pimodivir
human
hyperimmun
plasma
host
target
compound
danrixin
antagonist
verdinexor
nuclear
export
antagonist
inform
niaid
servic
avail
http
wwwniaidnihgovresearchmicrobiologyandinfectiousdiseasesresourc
lorant
leopold
janssen
titusvil
new
jersey
usa
pimodivir
formerli
novel
nonnucleotid
subunit
inhibitor
influenza
viral
polymeras
occupi
gtp
gtp
capbind
site
select
inhibit
product
mrna
byrn
et
al
lethal
mous
model
infect
treatment
mgkg
twice
daili
protect
mice
even
treatment
delay
day
byrn
et
al
protect
still
seen
delay
treatment
day
postinfect
human
challeng
model
drug
oral
avail
avail
metabolit
unchang
half
life
around
hour
fecal
elimin
metabol
effect
cytochrom
level
trial
evalu
safeti
dose
efficaci
among
patient
administ
singl
dose
mg
patient
given
multipl
dose
mg
twice
daili
day
common
advers
event
defin
loos
stool
phase
iib
trial
patient
given
mg
twice
daili
day
without
mg
oseltamivir
preliminari
result
show
signific
decreas
nasal
viral
load
auc
qrtpcr
pimodivir
treat
group
pimodivir
plu
mg
oseltamivir
show
greater
decreas
auc
mg
pimodivir
alon
ten
percent
sampl
resist
virus
previous
shown
occur
mutat
byrn
et
al
drugdrug
interact
oseltamivir
pitavastatin
oral
contracept
seen
cardiac
safeti
concern
phase
iii
trial
plan
winter
takeki
uehara
shionogi
osaka
japan
small
molecul
inhibitor
capdepend
endonucleas
pa
inhibitor
influenza
b
virus
hydrolyz
activ
form
uehara
et
al
inhibit
initi
viru
mrna
synthesi
prevent
viru
protein
product
vitro
inhibit
viru
replic
ec
around
nm
potent
compar
nai
mice
singl
dose
mgkg
reduc
titer
log
mgkg
reduc
lung
viru
titer
log
singl
dose
long
halflif
hour
phase
trial
administr
mg
dose
exceed
exposur
level
target
potenc
phase
ii
trial
influenza
posit
adult
patient
hour
symptom
onset
random
receiv
singl
dose
mg
placebo
nasalthroat
swab
taken
viru
titer
ec
determin
plaqu
assay
blood
sampl
taken
hour
posttreat
plasma
concentr
rapid
decreas
viru
load
log
hour
dose
show
hour
earlier
resolut
fever
hour
earlier
allevi
symptom
compar
placebo
group
mean
vs
hour
advers
event
similar
placebo
advers
drug
interact
higher
placebo
group
level
drug
plasma
hour
mostli
proport
dose
median
ec
isol
baselin
nmoll
nmoll
nmoll
type
b
virus
compar
earlier
studi
signific
neg
correl
drug
dose
chang
viru
titer
day
resist
studi
report
poster
shishido
et
al
isol
patient
infect
viru
infect
b
viru
substitut
pa
gene
pa
pa
reduc
susceptibl
plaqu
reduct
assay
man
wah
tan
genentech
south
san
francisco
california
usa
human
immunoglobulin
monoclon
antibodi
bind
highli
conserv
epitop
stalk
influenza
ha
block
hamedi
membran
fusion
endosom
promot
adcc
infect
cell
also
lead
direct
viru
bind
inhibit
releas
viru
genom
remain
bound
even
ph
prevent
unfold
fusion
peptid
neutral
known
human
influenza
strain
gupta
et
al
lethal
mous
model
dose
depend
protect
hour
postinfect
provid
protect
develop
treat
patient
hospit
influenza
phase
trial
demonstr
linear
serum
pharmacokinet
consist
human
antibodi
phase
iia
studi
subject
three
singledos
group
mg
receiv
intraven
hour
inocul
influenza
viru
mcbride
et
al
subject
start
cours
oseltamivir
twice
daili
day
exhibit
doseproport
serum
pk
doseproport
nasal
pk
pk
drugdrug
interact
oseltamivir
observ
treat
group
show
significantli
reduc
viru
burden
rtpcr
tcid
assay
mcbride
et
al
subject
maximum
nasal
concentr
c
max
greater
median
nasal
c
max
valu
shorter
time
resolut
viral
shed
compar
volunt
placebo
group
median
vs
hour
trial
plan
hospit
patient
compar
high
low
dose
plu
oseltamivir
compar
oseltamivir
alon
howev
challeng
remain
clinic
virolog
endpoint
yet
clearli
defin
broadli
neutral
human
antiha
antibodi
react
region
ha
stalk
conserv
group
influenza
virus
baranovich
et
al
tharakaraman
et
al
prevent
matur
ha
fusogen
form
thu
prevent
virusendosom
fusion
lethal
balbc
mous
model
viru
infect
administ
via
intraperiton
inject
either
singl
mg
kg
dose
hour
treat
mgkg
dose
hour
infect
baranovich
et
al
mckimmbreschkin
fri
prophylact
administr
antibodi
result
protect
mice
singl
administr
mgkg
hour
infect
also
provid
surviv
wherea
mgkg
dose
protect
virusinfect
oseltamivir
sensit
virusinfect
mice
oseltamivir
resist
undergon
recent
chang
pathogen
su
et
al
mutat
ha
includ
substitut
mab
bind
region
howev
mutat
lead
loss
bind
phase
trial
volunt
administ
singl
intraven
dose
mgkg
exposur
approxim
doseproport
mean
halflif
day
wollacott
et
al
suggest
singl
dose
suffici
drug
relat
seriou
ae
record
although
mild
diarrhea
prevent
pretreat
mg
benadryl
mg
ibuprofen
phase
ii
challeng
studi
decreas
viru
auc
qrtpcr
log
decreas
median
peak
viru
load
median
viral
load
undetect
sooner
median
time
resolut
symptom
shorter
around
day
carol
epstein
fujifilm
pharmaceut
boston
massachusett
usa
favipiravir
small
molecul
nucleosid
analogu
select
inhibit
rnadepend
rna
polymeras
influenza
mani
rna
virus
furuta
et
al
date
resist
vitro
patient
sampl
detect
report
previou
isirvavg
confer
two
phase
ii
dose
find
trial
signific
benefit
first
second
statist
signific
decreas
time
resolut
symptom
fever
mckimmbreschkin
fri
also
rapid
decreas
viru
titer
compar
placebo
group
two
phase
iii
trial
healthi
adult
uncompl
influenza
patient
treat
two
load
dose
mg
day
mg
bid
day
advers
effect
profil
appear
similar
untreat
patient
except
asymptomat
elev
uric
acid
trial
show
signific
antivir
effect
time
undetect
viru
cultur
shorten
one
day
two
phase
ii
iii
studi
approxim
decreas
time
resolut
symptom
one
trial
much
shorter
time
resolut
symptom
placebo
group
thu
make
harder
show
full
hour
decreas
treat
group
hour
differ
one
trial
hour
differ
howev
differ
strain
viru
predomin
two
trial
analysi
neutrophillymphocyt
ratio
nlr
measur
system
inflamm
show
differ
time
resolut
symptom
placebo
favipiravirtr
subject
increas
higher
nlr
current
analyz
retain
pk
sampl
cytokin
level
explor
concept
increas
benefit
patient
inflamm
jeanfrancoi
rossignol
romark
morristown
new
jersey
usa
nitazoxanid
ntz
small
mw
inhibitor
use
extens
treatment
giardia
cryptosporidium
infect
repurpos
treatment
influenza
viral
diseas
includ
piv
rsv
rossignol
shakya
et
al
block
matur
influenza
ha
posttransl
level
rossignol
paramyxovirus
target
f
protein
fold
inhibit
member
protein
disulfid
isomeras
famili
locat
endoplasm
reticulum
piacentini
et
al
silenc
cell
cultur
decreas
viru
replic
ntz
also
appear
decreas
proinflammatori
cytokin
pbmc
earlier
phase
iibiii
trial
recipi
acut
uncompl
influenza
mg
mg
twice
daili
day
associ
reduct
durat
symptom
hour
log
decreas
viru
titer
haffizulla
et
al
total
phase
iiiii
clinic
trial
patient
uncompl
influenza
b
show
drug
reduc
durat
influenza
ill
compar
placebo
p
stachulski
et
al
two
recent
complet
rdbpct
phase
iii
trial
ntz
given
oral
mg
twice
daili
monotherapi
day
compar
ntz
combin
oseltamivir
oseltamivir
alon
overal
differ
time
resolut
symptom
ntz
oseltamivir
ntz
oseltamivir
combin
vs
placebo
group
one
subset
studi
among
patient
age
mean
time
resolut
symptom
hour
compar
placebo
signific
daili
monitor
patient
thought
lead
better
outcom
sumita
royghanta
gsk
philadelphia
pennsylvania
usa
phase
ii
iii
clinic
trial
evalu
safeti
efficaci
intraven
zanamivir
treatment
patient
hospit
sever
influenza
conduct
despit
patient
suppli
intraven
zanamivir
ivz
compassion
use
global
challeng
meet
target
phase
ii
studi
phase
iii
studi
phase
ii
studi
subject
confirm
influenza
receiv
mg
ivz
bid
adult
ageadjust
weightbas
dose
bid
pediatr
day
safeti
clinic
pk
virolog
endpoint
marti
et
al
phase
iii
studi
carri
site
countri
patient
enrol
within
day
symptom
onset
receiv
ivz
ivz
bid
oseltamivir
os
mg
bid
day
marti
et
al
time
clinic
respons
composit
vital
sign
resolut
hospit
discharg
primari
endpoint
secondari
endpoint
includ
clinic
virolog
pk
safeti
virolog
assess
includ
nasopharyng
swab
throat
swab
endotrach
sampl
avail
approxim
day
improv
time
clinic
respons
mg
ivz
group
compar
oseltamivir
signfic
superior
differ
median
chang
viral
load
three
group
drug
sensit
evalu
phenotyp
analysi
munana
base
enzym
assay
cultur
upper
lower
respiratori
tract
sampl
phase
ii
studi
adult
pediatr
subject
enrol
adult
pediatr
prior
os
mean
ic
valu
within
expect
rang
yate
et
al
sequenc
analysi
reveal
three
adult
pediatr
subject
virus
baselin
resist
substitut
two
subject
virus
treatment
emerg
na
resist
substitut
howev
latter
abl
cultur
demonstr
lack
fit
phase
iii
studi
subject
enrol
confirm
influenza
prior
os
sampl
subject
cultur
posit
mean
os
zanamivir
ic
expect
rang
virus
subject
show
shift
suscept
nai
na
sequenc
phase
iii
subject
identifi
resist
substitut
subject
b
virus
present
day
thu
select
treatment
five
na
substitut
four
oseltamivir
arm
fifth
although
ivz
arm
prior
os
treatment
marti
et
al
four
treatmentassoci
nairesist
substitut
identifi
virus
could
cultur
two
os
day
day
two
day
day
marti
et
al
novel
zanamivir
resist
substitut
detect
clinic
studi
evalu
iv
zanamivir
sever
influenza
irina
leneva
mechnikov
research
institut
vaccin
sera
moscow
russia
ha
target
fusion
inhibitor
umifenovir
arbidol
licenc
russia
treatment
prophylaxi
influenza
b
infect
umifenovir
bind
hydrophob
caviti
ha
trimer
stem
interfac
two
protom
function
molecular
glue
umifenovir
stabil
prefus
conform
ha
inhibit
larg
conform
rearrang
associ
membran
fusion
low
ph
endosom
kadam
wilson
cell
cultur
umifenovir
inhibit
replic
influenza
b
virus
includ
nairesist
virus
resist
aros
serial
passag
viru
cultur
amino
acid
substitut
subunit
leneva
et
al
mice
challeng
viru
treat
oral
mgkgday
umifenovir
mgkg
enhanc
surviv
compar
placebo
group
leneva
et
al
lung
viru
titer
decreas
log
umifenovirtr
mice
retrospect
observ
studi
carri
leneva
et
al
season
patient
hospit
ili
treat
mg
umifenovir
mg
oseltamivir
within
hour
symptom
onset
durat
fever
influenzainfect
patient
treat
umifenovir
year
old
day
day
year
old
respect
compar
age
match
untreat
group
characterist
umifenovirtr
high
risk
patient
compar
untreat
high
risk
patient
studi
signific
differ
found
durat
ill
main
symptom
influenza
umifenovir
oseltamivir
treat
group
pneumonia
complic
influenza
observ
patient
treat
umifenovir
patient
receiv
antivir
therapi
p
none
patient
treat
oseltamivir
howev
note
poor
complianc
four
time
daili
dose
long
act
formul
need
well
pk
pd
studi
random
doubleblind
placebo
control
studi
evalu
safeti
toler
clinic
effect
oral
danirixin
treatment
adult
acut
uncompl
influenza
sumita
royghanta
gsk
philadelphia
pennsylvania
usa
oral
danirixin
dnx
select
competit
revers
inhibitor
cxc
chemokin
receptor
buschpetersen
et
al
key
receptor
chemotaxi
neutrophil
site
inflamm
oral
dnx
current
clinic
develop
uncompl
influenza
intraven
therapi
patient
hospit
influenza
rdb
pct
outpati
uncompl
influenza
evalu
safeti
toler
mg
dnx
without
mg
oseltamivir
patient
treat
twice
daili
five
day
patient
influenza
posit
qpcr
highest
incid
ae
placebo
group
follow
dnxo
dnx
os
group
treatment
group
mean
peripher
neutrophil
decreas
baselin
day
increas
day
therapi
resolv
day
confirm
bacteri
ae
patient
neutropenia
n
influenza
posit
agre
copd
studi
bacteri
ae
observ
patient
treat
mg
daili
week
trend
toward
shorter
median
time
resolut
influenza
symptom
dnxo
group
hour
os
group
hour
although
latter
unexpectedli
longer
placebo
decreas
pcr
viral
load
similar
treatment
group
includ
placebo
safeti
concern
recruit
hospit
studi
hua
wu
sab
biotherapeut
sioux
fall
sd
usa
transchromosom
tc
bovin
platform
use
tripl
knockout
bovin
immunoglobulin
ig
gene
includ
ig
h
chain
chain
replac
full
repertoir
human
ig
gene
tcbovin
produc
fullyhuman
immunoglobulin
higg
dye
et
al
upon
hyperimmun
antigen
choic
tcbovin
rapidli
produc
gram
specif
polyclon
higg
per
month
per
anim
anti
mer
higg
phase
trial
shown
seriou
ae
normal
pk
higg
immunogen
anoth
trial
higg
mycoplasma
homini
sab
shown
initi
sign
efficaci
without
ae
tcbovin
hyperimmun
trival
season
influenza
spilt
virion
use
produc
mous
model
lethal
influenza
viru
infect
dosag
evalu
prophylact
hour
infect
therapeut
h
postinfect
pi
singl
prophylact
dose
mgkg
provid
protect
singl
treatment
mgkg
dose
provid
protect
second
studi
therapeut
efficaci
compar
human
deriv
hyperimmun
antiinfluenza
ivig
treat
infect
mice
singl
dose
mgkg
antiinfluenza
human
ivig
h
pi
protect
provid
dose
mgkg
dose
human
antiinfluenza
ivig
provid
signific
protect
third
mous
studi
synergi
subtherapeut
dose
mgkg
oseltamivir
mgkg
evalu
compar
either
agent
alon
administ
h
pi
mice
receiv
combin
therapi
surviv
wherea
surviv
observ
mice
receiv
mgkg
alon
surviv
mice
receiv
mgkg
oseltamivir
alon
phase
human
trial
plan
barney
graham
vaccin
research
center
niaid
bethesda
maryland
usa
rsv
pneumoviru
famili
paramyxovirida
lead
caus
sever
respiratori
diseas
hospit
young
children
date
rsv
vaccin
unavail
number
challeng
imped
develop
young
age
statu
patient
seriou
diseas
multipl
viral
mechan
interfer
induct
effector
function
type
interferon
failur
natur
immun
protect
reinfect
tradit
difficult
boost
respons
adult
legaci
vaccineenhanc
diseas
graham
rsv
fusion
f
glycoprotein
mediat
viral
entri
cell
primari
antigen
target
vaccin
develop
recent
advanc
toward
defin
rsv
f
specif
neutralizationsensit
epitop
solv
structur
prefus
pref
postfus
postf
conform
trimer
f
glycoprotein
mclellan
et
al
led
better
understand
mechan
neutral
serolog
respons
natur
rsv
infect
vaccin
pathogenesi
diseas
mechan
viral
inactiv
liang
et
al
elucid
structur
function
f
glycoprotein
led
design
vaccin
antigen
recapitul
surfac
function
pref
molecul
stabil
pref
mutagenesi
improv
immunogen
primari
infect
infant
antibodi
postf
poor
neutral
abil
contrast
antibodi
adult
recogn
pref
form
clinic
trial
pref
rsv
vaccin
start
februari
structureguid
vaccin
antigen
design
appli
betacoronavirus
betacov
influenza
paramyxovirus
util
class
fusion
protein
entri
coronaviru
spike
protein
bind
cellular
receptor
mediat
membran
fusion
thu
determin
part
cell
tropism
host
rang
betacov
prefus
trimer
structur
multipl
glycoprotein
betacov
solv
alon
complex
neutral
monoclon
antibodi
kirchdoerf
et
al
suggest
may
possibl
defin
univers
solut
stabil
cov
prefus
trimer
mutagenesi
produc
highli
stabl
immunogen
cov
vaccin
antigen
immunogen
base
fulllength
plasmid
dna
subunit
protein
elicit
robust
serumneutr
activ
sever
merscov
strain
mice
nonhuman
primat
immun
rhesu
macaqu
confer
protect
merscovinduc
radiograph
pneumonia
assess
use
computer
tomographi
support
strategi
promis
approach
merscov
vaccin
develop
major
biolog
challeng
univers
influenza
vaccin
includ
rapid
antigen
genet
variat
particularli
within
zoonot
reservoir
potenti
increas
fit
among
reassort
adapt
mutat
preexist
immun
includ
immunodomin
serotypespecif
epitop
antibodi
lineag
limit
breadth
influenza
b
cell
phenotyp
sever
diseas
occur
extrem
age
vulner
popul
compromis
immun
new
technolog
particularli
structur
biolog
rapid
isol
human
monoclon
antibodi
highthrough
sequenc
protein
engin
singlecel
analysi
deriv
provid
new
strategi
influenza
vaccin
influenza
ha
discreet
structurallydefin
site
vulner
specif
antibodi
lineag
defin
provid
broad
immun
antigen
design
influenza
ha
base
fulllength
ha
ha
stem
ha
receptorbind
site
produc
pursu
distinct
strategi
elicit
crossprotect
antibodi
respons
vaccin
antigen
display
selfassembl
nanoparticl
elicit
high
magnitud
antibodi
respons
kanekiyo
et
al
futur
viral
vaccin
design
character
atomiclevel
protein
engin
preserv
critic
structur
trimer
fusion
machin
target
potent
broadli
crossreact
neutral
antibodi
technolog
structur
biolog
rapid
isol
human
monoclon
antibodi
high
throughput
sequenc
analysi
singl
sort
bcell
tcell
new
antigen
display
deliveri
option
dramat
chang
process
vaccin
develop
creat
new
opportun
prevent
respiratori
viral
infect
natur
infect
human
boost
crossgroup
stalkspecif
antibodi
respons
lu
liu
shanghai
public
health
clinic
center
shanghai
china
infect
influenza
viru
patient
develop
rel
weak
protect
antibodi
respons
measur
hai
neutral
antibodi
nab
titer
guo
et
al
known
howev
antibodi
protect
virus
influenza
strain
presenc
crossgroup
immun
respons
evalu
cohort
patient
hospit
shanghai
influenza
viru
infect
sera
adult
patient
age
hospit
influenza
obtain
earli
clinic
cours
day
onset
symptom
late
day
compar
age
match
asymptomat
noninfect
control
expect
infect
influenza
higher
hai
nab
bind
antibodi
bab
homolog
influenza
compar
control
infect
influenza
also
higher
hai
nab
bab
heterolog
virus
infect
influenza
viru
also
higher
antibodi
titer
use
repres
virus
subtyp
measur
elisa
use
recombin
ha
na
protein
substrat
antibodi
level
ha
higher
compar
control
group
virus
higher
group
virus
crossreact
antibodi
shown
neutral
higher
group
virus
higher
group
virus
use
pseudotyp
virus
increas
na
antibodi
titer
group
virus
group
na
antibodi
respons
head
stalk
evalu
separ
use
chimer
ha
headonli
construct
elisa
crossgroup
respons
larg
mediat
stalkspecif
antibodi
antistalk
antibodi
induc
earli
infect
wherea
antibodi
head
induc
later
singl
im
dose
plantmad
vlp
vaccin
bear
hemagglutinin
elicit
balanc
humor
cellular
respons
protect
young
age
mice
influenza
challeng
breanna
hodgin
mcgill
univers
montreal
quebec
canada
season
influenza
vaccin
effect
may
lower
adult
age
year
younger
adult
beyer
et
al
reduct
vaccin
effect
may
partial
explain
lower
immun
respons
vaccin
popul
goodwin
et
al
plantmad
viruslik
particl
vlp
resembl
influenza
may
immunogen
splitviru
formul
vlp
lack
genet
materi
mimic
viral
structur
display
target
protein
interest
develop
vlp
influenza
recombin
monomer
ha
protein
influenza
viru
express
nicotiana
benthamiana
close
rel
tobacco
plant
use
transient
express
vector
plant
harvest
plantproduc
vlp
recov
fraction
evalu
immunogen
young
week
age
month
femal
balbc
mice
given
singl
dose
ha
either
intranas
intramuscular
im
rout
two
control
first
mice
given
influenza
split
vaccin
im
inject
second
unvaccin
mice
three
week
postvaccin
hai
antibodi
detect
young
im
group
geometr
mean
titer
mice
challeng
subleth
dose
lethal
dose
influenza
viru
viral
challeng
young
im
group
lost
least
amount
weight
surviv
young
split
im
group
age
mice
vaccin
im
administr
vlp
also
minim
weight
loss
surviv
compar
split
vaccin
surviv
standard
young
mice
young
vlp
im
vaccin
group
greatest
fold
decreas
viral
load
compar
vaccin
group
among
age
anim
group
receiv
vlp
im
rout
greatest
fold
decreas
respect
compar
split
vaccin
group
although
administr
vlp
vaccin
elicit
detect
system
respons
young
age
anim
protect
challeng
susann
rauch
curevac
ag
tuebingen
germani
mrnabas
vaccin
allow
rapid
gener
sequenc
specif
clinicalgrad
materi
scalabl
costeffect
process
mrna
also
higher
safeti
profil
nt
cross
nuclear
barrier
encod
antigen
rapidli
chang
match
evolv
viral
strain
sinc
mrna
produc
basic
materi
product
site
rnactiv
one
mrna
base
vaccin
platform
initi
studi
intraderm
influenza
rnactiv
vaccin
gave
similar
hai
titer
mice
compar
quadrival
split
viru
vaccin
newer
formul
rnactiv
vaccin
lipid
encapsul
enabl
im
deliveri
rnactiv
abl
induc
potent
immun
respons
appli
im
use
low
dose
mrna
give
higher
hai
titer
compar
quadrival
nonencapsul
rnactiv
quadrival
split
viru
vaccin
vaccin
mice
rnactiv
formul
encod
influenza
ha
reveal
increas
humor
cellular
immun
respons
analyz
via
function
antibodi
level
ic
intracellular
cytokin
stain
cell
respect
compar
previou
rnactiv
formul
nonhuman
primat
studi
lipid
encapsul
formul
quadrival
rnactiv
vaccin
gave
good
antibodi
titer
declin
year
better
cellular
immun
respons
measur
intracellular
cytokin
stain
cell
martin
schutten
clinic
virolog
diagnost
noordholland
netherland
current
human
challeng
model
influenza
use
egggrown
virus
low
attack
rate
memoli
et
al
egg
adapt
human
virus
increas
affin
sia
galcontain
receptor
thu
improv
replic
egg
impair
abil
bind
sia
galtermin
receptor
like
decreas
fit
replic
human
gambaryan
et
al
wildtyp
noneggadapt
viru
may
better
challeng
model
influenza
viru
propag
time
mdck
cell
singl
passag
egg
three
cohort
healthi
volunt
intranas
inocul
increas
dose
influenza
cohort
cohort
cohort
tcid
ml
inclus
criteria
includ
mn
titer
less
equal
challeng
strain
overal
attack
rate
defin
least
two
consecut
posit
viral
load
qrtpcr
cohort
cohort
viral
shed
measur
auc
also
increas
increas
dose
cohort
cohort
cohort
qrtpcr
log
copi
dayml
quantit
cultur
log
tcid
dayml
respect
particip
baselin
mn
titer
equal
attack
rate
compar
mn
less
viral
auc
qrtpcr
log
copi
dayml
mn
equal
compar
mn
less
similar
result
found
viral
auc
quantit
cultur
log
tcid
dayml
compar
mean
composit
influenza
symptom
score
increas
higher
inoculum
cohort
cohort
cohort
bin
wang
key
laboratori
medic
molecular
virolog
moh
moe
fudan
univers
shanghai
china
rsv
infect
major
caus
respiratori
tract
diseas
children
year
old
prior
rsv
vaccin
effort
use
formalininactiv
rsv
vaccin
firsv
caus
sever
case
vaccineenhanc
diseas
ved
ved
may
due
lack
regulatori
cell
treg
cell
import
immunoregulatori
cell
control
inflamm
minim
tissu
damag
acosta
et
al
demonstr
firsv
vaccin
mous
model
cannon
et
al
inflamm
due
induct
respons
lung
overproduct
cytokin
led
neutrophil
infiltr
peribronchiol
alveol
castilow
et
al
low
dose
cyclosporin
csa
shown
induc
treg
respons
brandt
et
al
studi
evalu
strategi
immun
anim
recombin
rsv
g
protein
togeth
low
dose
csa
evalu
immunogen
recombin
g
protein
csa
femal
balbc
mice
immun
im
sc
day
day
recombin
g
protein
csa
alon
g
protein
csa
firsv
level
antirsv
antibodi
neutral
antibodi
higher
group
immun
g
protein
csa
compar
g
protein
alon
firsv
group
evalu
protect
efficaci
recombin
g
protein
csa
anim
challeng
pfu
rsv
strain
day
viral
load
lung
analyz
day
challeng
recombin
g
protein
csa
strategi
reduc
viral
load
lung
significantli
compar
g
protein
alon
p
firsv
p
lung
patholog
review
group
vaccin
g
protein
firsv
alon
demonstr
signific
perivascul
peribronchiol
alveol
wherea
recombin
g
protein
csa
group
minor
peribronchiol
nearli
normal
alveolar
morpholog
anim
receiv
recombin
g
protein
csa
higher
level
treg
cell
spleen
lymph
node
compar
vaccin
strategi
stimul
treg
respons
ad
csa
g
antivir
research
protein
vaccin
may
potenti
immun
respons
minim
vaccineenhanc
diseas
ding
oh
collabor
centr
refer
research
influenza
melbourn
australia
influenza
virus
amino
acid
substitut
na
glycoprotein
alter
drug
bind
caus
reduc
sensit
virus
nai
na
amino
acid
substitut
seen
virus
patient
undergo
oseltamivir
treatment
base
vitro
nai
suscept
assay
variant
virus
reduct
sensit
oseltamivir
epidemiolog
data
suggest
fit
transmiss
potenti
resist
virus
may
vari
strain
wong
et
al
evalu
fit
transmiss
potenti
resist
virus
ferret
infect
wildtyp
wt
variant
season
influenza
tcid
prophylaxi
model
oseltamivir
mgkgday
placebo
administ
uninfect
ferret
hour
prior
cohous
influenza
virusinfect
ferret
follow
twice
daili
dose
day
season
influenza
wt
viru
oseltamivir
fulli
prevent
infect
detect
viru
shed
clinic
sign
anim
infect
viru
oseltamivir
effect
viral
shed
activ
fever
bodi
weight
compar
control
howev
oseltamivirtr
ferret
decreas
nasal
inflamm
compar
control
viru
oseltamivir
prevent
infect
ferret
expos
wt
virus
effect
infect
clinic
symptom
variant
investig
effect
oseltamivir
treatment
mgkgday
oseltamivir
placebo
given
oral
ferret
hour
cohous
influenza
virusinfect
ferret
follow
twice
daili
dose
day
oseltamivir
effect
viral
shed
activ
fever
bodi
weight
nasal
inflamm
either
wt
infect
ferret
thu
make
unsuit
model
evalu
drug
susceptibl
jacki
chan
geneva
switzerland
late
first
influenza
pandem
centuri
global
influenza
program
develop
research
agenda
influenza
togeth
global
partner
goal
public
health
research
agenda
influenza
identifi
evid
need
better
understand
diseas
impact
strengthen
public
health
guidanc
action
essenti
limit
impact
pandem
zoonot
season
influenza
individu
popul
agenda
broadbas
public
health
research
strategi
influenza
organ
around
framework
five
key
research
area
stream
peerreview
journal
public
address
prioriti
research
question
agenda
updat
retain
three
major
substream
agenda
includ
factor
associ
pathogenesi
clinic
sever
improv
clinic
manag
patient
health
care
capac
respons
updat
includ
integr
revis
new
recommend
specif
research
initi
project
identifi
could
contribut
key
evid
improv
patient
manag
one
new
recommend
optim
use
current
antivir
treatment
includ
understand
barrier
avail
increas
util
treatment
influenza
higher
research
prioriti
recommend
optim
effect
current
novel
antivir
treatment
compris
develop
new
formul
deliveri
rout
system
antivir
drug
combin
strategi
address
emerg
treatment
antivir
resist
endpoint
make
sens
clinic
trial
sever
influenza
relat
ill
menno
de
jong
univers
amsterdam
amsterdam
holland
registr
trial
antivir
agent
influenza
histor
target
previous
healthi
patient
uncompl
influenza
outpati
set
focu
current
therapi
develop
howev
patient
underli
ill
hospit
sever
diseas
treanor
et
al
lack
formal
evid
efficaci
current
licens
agent
complic
lack
valid
clinic
endpoint
efficaci
studi
sever
ill
patient
ison
et
al
clinic
endpoint
includ
time
resolut
fever
time
normal
vital
sign
respiratori
heart
rate
blood
pressur
oxygen
satur
mortal
endpoint
hospit
patient
problemat
due
heterogen
clinic
background
diseas
sever
admiss
de
jong
et
al
marti
et
al
endpoint
includ
patient
report
outcom
questionnair
osborn
et
al
flupro
survey
power
et
al
virolog
endpoint
shown
good
correl
clinic
measur
carrat
et
al
viru
load
admiss
shown
correl
length
hospit
stay
clark
et
al
viru
load
may
thu
minim
issu
around
heterogen
popul
addit
ethic
carri
placebo
control
trial
current
requir
prove
superior
standard
care
usual
oseltamivir
therapi
remain
challeng
de
jong
et
al
combin
clinic
virolog
endpoint
may
necessari
achiev
consist
regin
lehnert
bfarm
germani
us
fda
issu
guidanc
document
develop
drug
treatment
andor
prophylaxi
influenza
fdacder
document
yet
avail
europ
new
antivir
dealt
individu
within
socal
scientif
advic
procedur
european
medicin
agenc
ema
concept
paper
guidelin
new
influenza
therapeut
develop
therapi
need
show
effect
sever
influenza
safe
well
toler
high
potenc
rapid
act
longer
treatment
window
nai
low
likelihood
resist
emerg
effect
known
resist
strain
may
effect
combin
anoth
therapi
singl
treatment
prefer
result
decreas
viru
load
none
current
approv
drug
demonstr
clinic
benefit
rct
patient
sever
influenza
diseas
challeng
studi
alway
reflect
natur
infect
result
previous
healthi
popul
extrapol
sever
diseas
patient
risk
complic
influenza
heterogen
respect
baselin
statu
meet
report
antivir
research
sever
diseas
well
type
sever
complic
may
lead
difficulti
design
valid
studi
due
preexist
immun
data
adult
may
alway
extrapol
children
studi
sever
influenza
use
time
normal
vital
sign
respiratori
function
anoth
endpoint
base
ordin
scale
given
point
time
first
administr
studi
drug
death
icu
mechan
ventil
icu
wo
mechan
ventil
hospit
floor
hospit
discharg
suggest
king
et
al
draft
euguidelin
evalu
medicin
product
indic
treatment
influenza
envisag
releas
earli
kimberley
armstrong
barda
washington
dc
usa
biomed
advanc
research
develop
author
barda
work
partner
develop
therapeut
hospit
influenzainfect
popul
understand
clinic
institut
attitud
toward
clinic
trial
design
hospit
influenza
popul
barda
conduct
feasibl
studi
send
questionnair
clinic
investig
work
previou
hospit
infecti
diseas
clinic
trial
question
three
potenti
arm
trial
oseltamivir
oseltamivir
new
drug
new
drug
monotherapi
uniqu
respons
countri
receiv
topic
cover
soc
hospit
influenza
patient
well
feasibl
use
investig
drug
monotherapi
hospit
subject
clinician
list
nai
soc
institut
regardless
global
region
howev
percentag
patient
receiv
nai
vari
region
lower
soc
would
predict
clinician
believ
clinic
studi
protocol
includ
investig
drug
arm
would
allow
institut
ask
likelihood
institut
review
board
ethic
committe
approv
us
particip
versu
european
particip
thought
approv
would
given
unit
state
clinician
believ
includ
investig
monotherapi
arm
would
neg
impact
abil
recruit
subject
versu
minim
impact
western
europ
given
challeng
alreadi
present
hospit
influenza
clinic
trial
includ
investig
drug
monotherapi
arm
could
restrict
clinic
site
avail
studi
hamper
abil
recruit
subject
william
fischer
univers
north
carolina
chapel
hill
north
carolina
usa
influenza
associ
myocard
iam
report
occur
adult
hospit
influenza
infect
may
occur
absenc
sever
respiratori
complic
case
fatal
influenza
b
histopatholog
find
iam
observ
patient
cardiac
sampl
avail
paddock
et
al
complic
iam
includ
congest
heart
failur
adult
patient
iam
patient
requir
advanc
cardiac
support
mortal
seller
et
al
oseltamivir
treatment
influenza
associ
signific
decreas
risk
recurr
cardiovascular
event
subject
histori
cardiovascular
diseas
casscel
et
al
neurolog
complic
influenza
includ
febril
convuls
enceph
encephalopathi
guillain
barr
syndrom
meijer
et
al
toma
et
al
influenza
associ
enceph
common
pediatr
patient
report
hospit
adult
mortal
rate
patient
may
residu
neurolog
deficit
seller
et
al
mri
appear
diagnost
ct
scan
meijer
et
al
michael
ison
northwestern
univers
chicago
illinoi
usa
respiratori
virus
caus
rang
infect
solid
organ
sot
hematopoiet
stem
cell
transplant
hsct
recipi
earli
onset
transplant
result
sever
prolong
infect
possibl
reject
influenza
parainfluenza
rsv
gener
caus
sever
infect
rhinovirus
sot
patient
diagnosi
difficult
may
fever
present
degre
lymphopenia
onset
diseas
higher
risk
cml
transplant
type
also
affect
sever
allohsct
autohsct
lung
sot
respiratori
virus
caus
rang
acut
direct
effect
ie
viral
pneumonia
longterm
complic
bronchiol
obliteran
bo
late
onset
airflow
obstruct
earli
antivir
therapi
oseltamivir
result
lower
progress
pneumonia
reduc
need
iculevel
care
lower
mortal
lower
incid
bo
influenza
kumar
et
al
event
resist
oseltamivir
treatment
zanamivir
initi
two
phase
ii
studi
provid
proof
princip
antirsv
therapi
reduc
develop
bo
lung
transplant
recipi
waghmar
et
al
studi
hospit
infant
underway
nucleosid
analog
target
rsv
polymeras
phase
ii
trial
underway
hospit
adult
transplant
recipi
oral
rsv
entri
inhibitor
waghmar
et
al
replac
inhal
ribavirin
oral
ribavirin
also
investig
inhal
sialidas
undergo
clinic
develop
treatment
piv
adult
children
russel
ison
waghmar
et
al
although
failur
report
due
coinfect
bacteria
fungu
corticosteroid
statin
adjunct
therapi
sari
david
hui
chines
univers
hong
kong
hong
kong
sar
china
system
corticosteroid
use
frequent
treatment
influenza
relat
ard
howev
metaanalysi
data
predominantli
relat
treatment
sever
influenza
caus
viru
shown
system
corticosteroid
associ
increas
mortal
ci
rodrigo
et
al
comparison
control
highdos
corticosteroid
mgd
methylprednisolon
eqv
associ
increas
risk
day
mortal
vs
p
day
mortal
vs
p
longer
viral
shed
vs
day
p
patient
viral
pneumonia
differ
low
dose
mgd
methylprednisolon
control
studi
critic
ill
patient
infect
influenza
requir
invas
mechan
ventil
imv
addit
mammalian
target
rapamycin
mtor
inhibitor
sirolimu
mgd
day
oseltamivir
prednisolon
n
associ
higher
frequenc
liber
imv
vs
p
shorter
meet
report
antivir
research
durat
imv
vs
day
p
higher
chanc
achiev
lower
respiratori
tract
viral
rna
neg
day
vs
p
without
addit
sirolimu
n
studi
adult
hospit
shown
tripl
combin
day
clarithromycin
mg
naproxen
mg
oseltamivir
mg
twice
daili
follow
day
oseltamivir
reduc
mortal
length
hospitalstay
versu
oseltamivir
mg
twice
daili
without
placebo
day
control
hung
et
al
contrast
anoth
rct
compar
dual
therapi
oseltamivir
azithromycin
oseltamivir
alon
shown
signific
antiinflammatori
effect
adjunct
macrolid
treatment
adult
sever
influenza
infect
although
viru
control
unimpair
exploratori
posthoc
metaanalysi
studi
sar
sever
influenza
show
signific
reduct
pool
odd
mortal
follow
convalesc
treatment
vs
placebo
therapi
ci
mairjenkin
et
al
mutagenesi
analysi
identifi
determin
neuraminidas
inhibitor
resist
influenza
virus
subtyp
huil
yen
univers
hong
kong
hong
kong
sar
china
human
infect
virus
occur
random
mutagenesi
sitedirect
mutagenesi
use
investig
potenti
na
substitut
protein
may
confer
resist
nai
would
use
treatment
patient
infect
virus
pool
recombin
virus
contain
random
mutat
na
head
domain
passag
vitro
increas
concentr
oseltamivir
zanamivir
na
mutat
includ
viru
viru
identifi
serial
passag
howev
none
mutat
directli
confer
resist
nai
introduc
respect
recombin
virus
introduc
na
substitut
previous
report
confer
resist
nai
subtyp
sitedirect
mutagenesi
recombin
virus
respect
confer
compar
fulli
ident
resist
profil
respect
group
group
na
protein
avwg
substitut
decreas
replic
compar
wt
viru
previou
confer
updat
provid
variou
antivir
vaccin
influenza
rsv
respiratori
virus
preclin
clinic
studi
issu
remain
determin
appropri
clinic
virolog
endpoint
antivir
therapi
baselin
clinic
paramet
clearli
differ
previous
healthi
patient
compar
high
risk
hospit
patient
clinic
trial
new
influenza
viru
inhibitor
show
potenc
decreas
viru
titer
upper
respiratori
tract
like
tripl
combin
therapi
oseltamivir
ribavirin
amantadin
howev
improv
clinic
benefit
contrast
broadli
neutral
anti
ha
monoclon
antibodi
led
earlier
decreas
viru
level
well
earlier
resolut
symptom
rsv
antif
polymeras
inhibitor
show
promis
greater
reduct
viru
load
decreas
mucu
weight
compar
placebo
group
niaid
support
tri
facilit
develop
novel
therapi
vaccin
respiratori
virus
given
season
natur
virus
enrol
suffici
patient
clinic
trial
remain
challeng
especi
multipl
therapi
pipelin
trial
nelson
lee
previous
receiv
honoraria
consult
work
remuner
lectur
shionogi
ltd
janssen
pharmaceut
inc
astrazeneca
hong
kong
ltd
visterra
ltd
seqiru
inc
support
travel
meet
sanofiaventi
hong
kong
ltd
msd
asia
ltd
pfizer
corpor
hong
kong
ltd
gilead
scienc
hong
kong
ltd
janssen
pharmaceut
inc
author
noth
declar
